Eckman Mark H, Alonso-Coello Pablo, Guyatt Gordon H, Ebrahim Shanil, Tikkinen Kari A O, Lopes Luciane Cruz, Neumann Ignacio, McDonald Sarah D, Zhang Yuqing, Zhou Qi, Akl Elie A, Jacobsen Ann Flem, Santamaría Amparo, Annichino-Bizzacchi Joyce Maria, Bitar Wael, Sandset Per Morten, Bates Shannon M
Division of General Internal Medicine and Center for Clinical Effectiveness, University of Cincinnati, USA.
Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada; Iberoamerican Cochrane Centre, CIBERESP-IIB Sant Pau, Barcelona, Spain.
Thromb Res. 2015 Aug;136(2):341-7. doi: 10.1016/j.thromres.2015.05.020. Epub 2015 May 22.
Women with a history of venous thromboembolism (VTE) have an increased recurrence risk during pregnancy. Low molecular weight heparin (LMWH) reduces this risk, but is costly, burdensome, and may increase risk of bleeding. The decision to start thromboprophylaxis during pregnancy is sensitive to women's values and preferences. Our objective was to compare women's choices using a holistic approach in which they were presented all of the relevant information (direct-choice) versus a personalized decision analysis in which a mathematical model incorporated their preferences and VTE risk to make a treatment recommendation.
Multicenter, international study. Structured interviews were on women with a history of VTE who were pregnant, planning, or considering pregnancy. Women indicated their willingness to receive thromboprophylaxis based on scenarios using personalized estimates of VTE recurrence and bleeding risks. We also obtained women's values for health outcomes using a visual analog scale. We performed individualized decision analyses for each participant and compared model recommendations to decisions made when presented with the direct-choice exercise.
Of the 123 women in the study, the decision model recommended LMWH for 51 women and recommended against LMWH for 72 women. 12% (6/51) of women for whom the decision model recommended thromboprophylaxis chose not to take LMWH; 72% (52/72) of women for whom the decision model recommended against thromboprophylaxis chose LMWH.
We observed a high degree of discordance between decisions in the direct-choice exercise and decision model recommendations. Although which approach best captures individuals' true values remains uncertain, personalized decision support tools presenting results based on personalized risks and values may improve decision making.
有静脉血栓栓塞(VTE)病史的女性在孕期复发风险会增加。低分子量肝素(LMWH)可降低这种风险,但成本高、使用不便,且可能增加出血风险。孕期开始血栓预防的决策对女性的价值观和偏好很敏感。我们的目标是比较女性采用整体方法(向她们提供所有相关信息的直接选择法)与个性化决策分析(一种数学模型纳入她们的偏好和VTE风险以给出治疗建议)时的选择。
多中心国际研究。对有VTE病史、正在怀孕、计划怀孕或考虑怀孕的女性进行结构化访谈。女性根据使用VTE复发和出血风险个性化估计的情景表明她们接受血栓预防的意愿。我们还使用视觉模拟量表获取女性对健康结果的价值观。我们为每位参与者进行个性化决策分析,并将模型建议与直接选择练习时做出的决策进行比较。
在该研究的123名女性中,决策模型建议51名女性使用LMWH,建议72名女性不使用LMWH。决策模型建议进行血栓预防的女性中有12%(6/51)选择不使用LMWH;决策模型建议不进行血栓预防的女性中有72%(52/72)选择使用LMWH。
我们观察到直接选择练习中的决策与决策模型建议之间存在高度不一致。虽然哪种方法最能反映个体的真实价值观仍不确定,但基于个性化风险和价值观呈现结果的个性化决策支持工具可能会改善决策。